ORPHA.CO - Orphazyme A/S
| Previous close | 3.4750 |
| Open | 3.4950 |
| Bid | 2.9000 x 0 |
| Ask | 2.9700 x 0 |
| Day's range | 2.6100 - 3.8550 |
| 52-week range | 0.6750 - 5.3700 |
| Volume | |
| Avg. volume | 439,940 |
| Market cap | 102.582M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Change in management
The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023. Anders Fink Vadsholt states:” With the latest progress in our US security class act
- Globe Newswire
Resolutions passed at the Annual General Meeting
Company announcement Orphazyme A/SNo. 8/2023 Ole Maaløes Vej 3DK-2200 Copenhagen N www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting: Financial year 2022 Took note of the Board of Directors’ report on the Company’s activities in the past financial year;Adopted the Company’s annual report for 2022Adopted that the profit related to the financial
- Globe Newswire
Changes to the Board of Directors
Company announcement Orphazyme A/SNo. 07/2023 Ole Maaløes Vej 3DK-2200 Copenhagen N www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected a
- Globe Newswire
Major shareholder announcement
Company announcement Orphazyme A/SNo. 06/2023 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, May 12, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Scandinavian Investment Group A/S that Scandinavian Investment Group A/S holds shares, corresponding to more than 5% of the total share capital and voting rights in the Company. T
- Globe Newswire
Notice to convene Annual General Meeting
Company announcement Orphazyme A/SNo. 03/2023Ole Maaløes Vej 3DK-2200 Copenhagen N www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, April 25, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), today announces the notice to convene the Company’s Annual General Meeting to be held on: Wednesday, May 17, 2023 at 11:00 AM (CEST) at the offices of Gorrissen Federspiel, Axeltorv 2, DK-1609 Copenhagen V. The notice to convene the Annual General Meeting, including Appendix 1: Candida
- Globe Newswire
Orphazyme Announces Publication of 2022 Financial Results and Annual Report
Company announcement Orphazyme A/SNo. 02/2023 Ole Maaløes Vej 3DK-2200 Copenhagen Nwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, April 25, 2023 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today announced its financial results for the period from January 1, 2022, to December 31, 2022, and publishes its Annual Report. Anders Vadsholt, Chief Executive Officer and Chief Financial Officer said, “Orphazyme changed substantially in 2022, culminating in us now ha
- Globe Newswire
Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States
Company announcement Orphazyme A/SNo. 01/2023 Ole Maaløes Vej 3DK-2200 Copenhagen Nwww.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, April 17, 2023 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), announces that publication of its financial results for the full year ending December 31, 2022, previously expected April 19, 2023, are now expected to be published on April 25, 2023. Additional time is required to conclude the presentation of the financial statements.
- Globe Newswire
Orphazyme reports financial results in Interim Report First Half 2022
Company announcementOrphazyme A/SNo. 36/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, September 26, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) today announces its Interim Report First Half 2021 for the period January 1 – June 30, 2022. Anders Vadsholt, Chief Executive Officer and Chief Financial Officer said, “During the first half of 2022, we executed the sale of substantially all of Orphazyme’s assets, including the continuing development of arimoclomol, to
- Globe Newswire
Adjusted financial outlook for 2022
Orphazyme A/SCompany announcement No. 35/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, September 25, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) has decided to adjust its outlook for 2022, as published on June 7, 2022. The change is driven by the separation of activities into continuing and discontinued operations. The discontinued activities are related to the sale of assets to KemPharm A/S. The continuing business activities are the limited ongoing operationa
- Globe Newswire
Updated financial calendar for 2022
Company announcement Orphazyme A/SNo. 34/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, September 19, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) announces an update to the Company’s financial calendar in regard to the publication of the Company’s Interim Report First Half 2022. The Interim Report First Half 2022 will be published on September 26, 2022, previously September 20, 2022. Additional time is required to conclude the presentation of the financial state
- Globe Newswire
Updated notice to holders of ADSs regarding termination of Deposit Agreement
Orphazyme A/SCompany announcement No. 32/2022www.orphazyme.comCompany Registration No. 32266355 NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”) EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”) REPRESENTING DEPOSITED COMMON SHARES OF:ORPHAZYME A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 687305102 AND UNDERLYING ISIN: DK0060910917 Copenhagen, Denmark, June 20, 2022 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), hereby provides notice to holders of American Depositary Shares
- Globe Newswire
Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Orphazyme A/SCompany announcementNo. 30/2022 Annual reportwww.orphazyme.com Company Registration No. 32266355 [Correction: Hereby including the ESEF versions] Copenhagen, Denmark, June 7, 2022 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report. In 2021, and until recently, the primary focus of Orphazyme was on seeking marketing authorization in the United States
- Globe Newswire
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Orphazyme A/SCompany announcementNo. 30/2022 Annual reportwww.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, June 7, 2022 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report. In 2021, and until recently, the primary focus of Orphazyme was on seeking marketing authorization in the United States and Europe for its investigational product candid
